Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma
Pulmonary Pharmacology and Therapeutics, Volume 19, No. 6, Year 2006
Notification
URL copied to clipboard!
Description
Background: Inhaled corticosteroids are the mainstay of therapy in asthma, but local and systemic side effects and adherence remain a concern. Ciclesonide is an inhaled corticosteroid with on-site lung activation that provides potent anti-inflammatory activity and has been shown to have a good safety profile, even at high doses. Objective: The aim of this study was to compare the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate at comparable daily doses in patients with asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel group study, 529 patients were randomized to ciclesonide 160 μg once daily or fluticasone propionate 88 μg twice daily for 12 weeks. The primary endpoint was change in lung function. Results: Both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1 s, forced vital capacity, and morning peak expiratory flow compared with baseline (p < 0.0001 for all variables). Both medications reduced asthma symptoms and rescue medication use within the first 24 h. At the tested dose, both medications were equally safe and well tolerated. Conclusion: Ciclesonide 160 μg once daily was as effective as fluticasone propionate 88 μg twice daily in improving lung function and asthma symptoms, and in reducing rescue medication use in patients with asthma. © 2005 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Buhl, Roland Otto
Germany, Mainz
Universitätsmedizin Mainz
Vinkler, Ilona
Hungary, Nyiregyhaza
'josa Andras' Hospital of Szabolcs-szatmar County
Magyar, Pál
Hungary, Budapest
Általános Orvostudományi Kar
Györi, Zsuzsa
Hungary, Balassagyarmat
Institute of Pulmonology
Rybacki, Cezary
Poland, Bydgoszcz
Wojkowski Szpital Kliniczny
Middle, Michelle Vivienne
South Africa, George
South Africa Clinical Trials Ltd.
Escher, Armella
Norway
Nycomed
Engelstätter, Renate
Norway
Nycomed
Statistics
Citations: 8
Authors: 8
Affiliations: 7
Identifiers
Doi:
10.1016/j.pupt.2005.10.003
ISSN:
10945539
e-ISSN:
15229629
Research Areas
Disability